What do the latest data tell us about the role of targeted therapy in early-stage NSCLC?
Dr Stephen Liu discusses the current status and the challenges of adjuvant and neoadjuvant therapy in early-stage non-small cell lung cancer (NSCLC). He reviews the latest data on the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the adjuvant setting and their potential impact on clinical practice.view bio and disclosures 1/3 Next Chapter
How do recent data impact the future mutation testing guidelines in NSCLC?
Dr Liu talks us through the journey of a patient with early-stage non-small cell lung cancer (NSCLC), from diagnosis to surgical treatment and postoperative adjuvant therapy. He then describes the existing and emerging biomarkers and molecular tests which can aid the decision of whether a patient will benefit from adjuvant therapy and which therapy should be chosen.view bio and disclosures 2/3 Next Chapter
How do recent data in early-stage NSCLC impact the current treatment pathway for EGFR-mutant NSCLC?
Dr Stephen Liu discusses the importance of involving a multidisciplinary team (MDT) in assessing the optimal treatment and managing patient care. He talks about the challenges in integrating testing for response to targeted therapy into the patient’s clinical pathway and how the involvement of the MDT can optimize clinical decision making.view bio and disclosures 3/3 Leave Feedback
Overview & Learning Objectives
Watch as Dr Stephen Liu discusses how the latest clinical evidence on the use of EGFR-TKIs in the adjuvant setting is shaping the treatment paradigm in early-stage NSCLC and how the collaborative approach of a multidisciplinary team is essential to integrate a personalized approach to patient management.
After watching this activity, participants should be better able to:
- Recall the latest efficacy and safety data for EGFR-TKIs for patients with early-stage EGFR-mutant NSCLC
- Describe how the evolving use of EGFR-TKIs may impact the current recommendations for mutation testing in NSCLC
- Discuss how EGFR-TKIs may be incorporated into the evolving treatment pathway for early-stage NSCLC, now and in the future
Faculty & Disclosures
Dr Stephen Liu
Georgetown University Medical Center, Washington, DC, USA
Stephen Liu, MD, is an Associate Professor of Medicine and the Director of Thoracic Oncology at Georgetown University.
Dr Liu is the current Head of the Phase I, Developmental Therapeutics program at the Lombardi Comprehensive Cancer Center and his focus is on the treatment of lung cancer and novel drug development.
His research has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology and Cancer Discovery. In addition to leading national and global clinical trials for the treatment of lung cancer, Dr Liu has also served as the chief editor for Frontiers in Thoracic Oncology since 2014.
Dr Stephen Liu discloses: Advisory board/consultant roles for AstraZeneca, BeiGene, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Co., G1 Therapeutics, Inc., Genentech/Roche, Guardant Health, Inivata Limited, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Merck/Merck Sharp & Dohme Corp., PharmaMar S.A., Pfizer Inc., Regeneron Pharmaceuticals and Takeda; Research grants to his institution from Alkermes, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Corvus Pharmaceuticals, Eli Lilly and Co., Genentech, Lycera Corp., Merck, Merus, Pfizer Inc., Rain Therapeutics Inc., RAPT Therapeutics, Spectrum Therapeutics and Turning Point Therapeutics, Inc.